Eli Lilly and Company (LLY) Rating Reiterated by Morgan Stanley
Eli Lilly and Company (NYSE:LLY)‘s stock had its “hold” rating reissued by research analysts at Morgan Stanley in a research report issued on Friday. They presently have a $86.00 price objective on the stock. Morgan Stanley’s price target would indicate a potential upside of 4.32% from the company’s previous close.
A number of other equities analysts also recently issued reports on LLY. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a report on Monday. Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 price objective (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Finally, Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $93.00 to $90.00 in a report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $88.27.
Eli Lilly and (NYSE:LLY) traded down 0.76% during mid-day trading on Friday, reaching $82.44. 5,353,128 shares of the company traded hands. The company’s 50-day moving average is $80.90 and its 200-day moving average is $82.06. The stock has a market capitalization of $86.97 billion, a price-to-earnings ratio of 35.67 and a beta of 0.34. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 earnings per share. Equities analysts predict that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 825,000 shares of company stock worth $68,456,650 over the last ninety days. 0.20% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Pathstone Family Office LLC boosted its position in Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after purchasing an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. purchased a new position in Eli Lilly and in the second quarter worth about $494,000. Acrospire Investment Management LLC boosted its position in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and in the second quarter worth about $129,000. Finally, Heritage Trust Co purchased a new position in Eli Lilly and in the first quarter worth about $135,000. 75.77% of the stock is currently owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.